Skip to main content

Scovell 22

Page 1

Published in

2022

March 2022, Volume 9, Issue 2, Pages 173-180; doi: 10.1097/UPJ.0000000000000291

IsoPSA Reduces Provider Recommendations for Biopsy and Magnetic Resonance Imaging in Men with Total Prostate Specific Antigen ≥4 ng/mL: A Real-World Observational Clinical Utility Study Jason M. Scovell, Daniel Hettel, Robert Abouassaly, Nima Almassi, Ryan Berglund, Todd Breaux, Christopher Weight, Wahib Isac, Anna Zampini, Elizabeth Stark, Robert Rochelle, Aimee Kestranek, Mark Stovsky, and Eric A. Klein

Objective Methodology

To assess the impact of the IsoPSA test for prostate cancer risk assessment on provider patient management decisions in a real-world clinical setting. Enrolled 900 men being evaluated for prostate cancer; 734 met inclusion criteria (age >50 years, total serum prostate specific antigen (PSA) ≥4 and <100 ng/mL and no history of prostate cancer). Compared biopsy and MRI recommendations prior to and after receiving IsoPSA results. Primary outcome: Number of biopsy and MRI recommendation changes occurring after IsoPSA testing.

Results

IsoPSA results were used to affirm or modify provider recommendations for prostate biopsy and/or MRI. • 60% change in recommendations for biopsy

- 90% of patients initially recommended for biopsy were not recommended for biopsy after clinicians received IsoPSA results ≤ 6

- 43% of patients initially NOT recommended for biopsy were recommended for biopsy after clinicians received IsoPSA results > 6

• 55% reduction in recommendations for prostate biopsy overall

Conclusion

In a real-world clinical setting, providers readily adopted IsoPSA with substantial reductions in the rate of recommended prostate biopsies and MRIs in patients with elevated PSA values (≥4 ng/mL). There was a high concordance between recommendation for or against prostate biopsy and the IsoPSA result. IsoPSA could help avoid biopsy-related discomfort and complications and reduce overdetection of indolent disease.


TRIAGE PATIENTS MORE EFFECTIVELY AND EFFICIENTLY CONSISTENT PERFORMANCE FOR BIOPSY NAÏVE AND REPEAT BIOPSY

Changes in recommendations for biopsy were identical for patients whether they had a previous negative biopsy or were biopsy naïve.

Summary of biopsies recommended before and after IsoPSA results by patient biopsy history No. Biopsies No. Biopsies % Reduction Recommended Recommended in Biopsies before IsoPSA after IsoPSA Recommended

Cohort

No.

All Subjects

734

638

284

55.5

Biopsy naïve

408

370

173

53.2

Prior neg biopsy

326

268

113

57.8

EFFICIENT PRACTICE MANAGEMENT Incorporating IsoPSA test into practice management efficiently triages elevated PSA patients into biopsy, MRI, or monitoring. IsoPSA has been incorporated into practice workflows before and after MRI demonstrating the clinical utility. ive

at

tPSA > 4

IsoPSA

g Ne

Po sit ive

Monitoring ive at

g

MRI

Ne

Po sit ive

TRUS Guided Biopsy

MR-US Fusion Biopsy

View this and other IsoPSA publications

Learn more about IsoPSA at IsoPSA.com 3615 Superior Ave. Suite 4407C ©2023 Cleveland Diagnostics, IsoPSA and all associated logos are trademarks of Cleveland Diagnostics, Inc. MKTG-VSA005

Cleveland, OH 44114


Turn static files into dynamic content formats.

Create a flipbook
Scovell 22 by clevelanddx - Issuu